Lipegfilgrastim
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Lipegfilgrastim
- Lipegfilgrastim: From Neutropenia Support (Original Indication Not Recorded) to Primary Release Disorder of Platelets
Lipegfilgrastim: From Neutropenia Support (Original Indication Not Recorded) to Primary Release Disorder of Platelets
One-Sentence Summary
Lipegfilgrastim is a long-acting (pegylated) G-CSF analog. The approved indication text is not recorded in the data compiled for this report, but drugs of this class are used to shorten neutropenia. The TxGNN model predicts it may be effective for primary release disorder of platelets, but 0 clinical trials and 0 publications currently support this direction, so it is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the approved indication text of the Singapore licence |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, lipegfilgrastim is a pegylated G-CSF analog. It acts on the neutrophil lineage through the G-CSF receptor.
Primary release disorder of platelets is a qualitative platelet function defect, in which platelets fail to secrete their granule contents properly. G-CSF has no established mechanism for correcting such a defect. The high TxGNN score is a network-based prediction only, likely reflecting graph proximity to other haematological disorders rather than a biological rationale. No trials or literature were available to support it.
Other top-ranked predictions show the same pattern. They include severe nonproliferative diabetic retinopathy (99.91%), pseudo-von Willebrand disease (99.91%), Glanzmann thrombasthenia (99.91%) and diabetic retinopathy (99.75%). None has supporting trials or literature, and none has a plausible mechanistic link. For drug-induced osteoporosis (98.64%), G-CSF exposure has been associated with bone remodelling changes, which suggests a possible adverse rather than therapeutic relationship.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16019P | LONQUEX SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6MG/0.6ML (Teva Pharmaceutical Industries Ltd.) | Injection, solution | Not recorded |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or publications, and the mechanism (G-CSF receptor agonism on neutrophils) does not plausibly address a platelet secretion defect. Safety label data and the approved indication text are also missing from the data compiled for this report.
To proceed, the following is needed:
- The Singapore package insert (warnings, contraindications and approved indication), obtained from the HSA website
- Detailed mechanism of action data, for example from DrugBank
- Preclinical or clinical evidence linking G-CSF receptor signalling to platelet release function
- A review of whether any of the other predicted indications has stronger biological support, since none currently does
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.